In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment

Leuk Res. 2019 Jan:76:11-14. doi: 10.1016/j.leukres.2018.11.008. Epub 2018 Nov 16.

Abstract

In this work, we investigated the stability of arsenic trioxide (ATO) used in leukemia treatment, encapsulated with nanoliposome, with the aid of ultrasound treatment. Stability studies of As species were followed by liquid chromatography-inductively coupled plasma mass spectrometry (LC-ICP-MS), allowing for the detection of the conversion of low amounts of As(III) to As(V) or the formation of other As species. The influence of storage temperature and time on ATO was evaluated. Low amounts of As(III) to As(V) conversions were observed when the As encapsulated with nanoliposome was incubated at 25 °C and 40 °C. However, As(III) was stable if the solution was maintained at 5 °C, even after 90 days. No formation of other As species was observed, indicating good stability of the encapsulated ATO. Next step of the work will focus on spray drying of ATO nanoliposomes-encapsuleted with the aim of long term stability of As.

Keywords: Arsenic species; Arsenic trioxide; Liposome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology
  • Arsenic Trioxide / administration & dosage*
  • Arsenic Trioxide / chemistry*
  • Arsenic Trioxide / pharmacology
  • Cell Line, Tumor
  • Chromatography, Liquid
  • Drug Stability
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Liposomes
  • Mass Spectrometry

Substances

  • Antineoplastic Agents
  • Liposomes
  • Arsenic Trioxide